Millennium Management LLC Has $171,000 Position in Codexis, Inc. (NASDAQ:CDXS)

Millennium Management LLC lowered its stake in shares of Codexis, Inc. (NASDAQ:CDXS) by 97.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 35,931 shares of the biotechnology company’s stock after selling 1,364,128 shares during the period. Millennium Management LLC’s holdings in Codexis were worth $171,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of CDXS. Tallon Kerry Patrick acquired a new stake in shares of Codexis during the 4th quarter valued at $2,018,000. White Pine Capital LLC boosted its stake in shares of Codexis by 28.1% during the 4th quarter. White Pine Capital LLC now owns 193,936 shares of the biotechnology company’s stock valued at $925,000 after buying an additional 42,512 shares during the period. Rhumbline Advisers boosted its stake in shares of Codexis by 10.5% during the 4th quarter. Rhumbline Advisers now owns 115,080 shares of the biotechnology company’s stock valued at $549,000 after buying an additional 10,902 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Codexis by 8.6% during the 4th quarter. Bank of New York Mellon Corp now owns 220,876 shares of the biotechnology company’s stock valued at $1,054,000 after buying an additional 17,429 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in Codexis by 12.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 239,720 shares of the biotechnology company’s stock valued at $1,143,000 after acquiring an additional 26,052 shares during the last quarter. Institutional investors and hedge funds own 78.54% of the company’s stock.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Codexis to a “sell” rating in a research note on Friday, May 16th.

Codexis Stock Down 4.7%

Codexis stock opened at $2.25 on Friday. The company has a market capitalization of $186.40 million, a P/E ratio of -2.59 and a beta of 2.52. The firm’s fifty day simple moving average is $2.33 and its 200-day simple moving average is $3.52. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39. Codexis, Inc. has a 1-year low of $1.90 and a 1-year high of $6.08.

Codexis (NASDAQ:CDXS) last released its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.05). The business had revenue of $7.54 million for the quarter, compared to the consensus estimate of $10.38 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. Sell-side analysts forecast that Codexis, Inc. will post -0.77 earnings per share for the current fiscal year.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.